LLY vs RANI

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Rani Therapeutics possesses a highly disruptive RaniPill platform offering oral delivery of biologics, targeting a massive unmet market need with exponential growth potential. The most significant development since the last analysis is the successful $60.3M private placement in late March 2026, which extended the cash runway from 2-5 months to Q4 2027. This materially de-risks the company from imm...